K

Kern Research | Bakersfield, CA

Research site
(Unclaimed)
Location
1921 18th Street, Bakersfield, California, United States of America
Site insights

Top conditions

Urticaria (7 trials)

Chronic Urticaria (5 trials)

Dermatitis (3 trials)

Eczema (3 trials)

Atopic Dermatitis (3 trials)

Top treatments

Rocatinlimab
Remibrutinib
CDX-0159
Dupilumab
OPN-375
LY3454738
LOU064
Astegolimab
MTPS9579A

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

13 of 17
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

The purpose of this trial is:to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to < 18 years of...

Enrolling
Chronic Spontaneous Urticaria
Drug: placebo
Drug: LOU064 (blinded)

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in...

Active, not recruiting
Chronic Spontaneous Urticaria
Biological: barzolvolimab
Drug: Matching Placebo

The coprimary objectives of the study are to:evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineu...

Enrolling
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The primary objectives of this study are to:estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus re...

Active, not recruiting
Atopic Dermatitis
Moderate-to-severe Atopic Dermatitis
Drug: Placebo
Drug: Rocatinlimab

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in...

Active, not recruiting
Chronic Inducible Urticaria
Biological: barzolvolimab
Drug: Matching Placebo

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Placebo
Drug: Astegolimab

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension...

Enrolling
Chronic Inducible Urticaria
Other: Placebo
Drug: Remibrutinib

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participant...

Enrolling
Chronic Spontaneous Urticaria
Drug: LOU064 (blinded)
Drug: LOU064 (open label)

The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO.This is a master protocol whic...

Enrolling
Pruritus
Drug: Fexofenadine (loratadine if not available)
Drug: Placebo

A research study of how house dust mite tablets work compared to placebo in children aged between 5 and 11 years and who have allergy to house dust m...

Active, not recruiting
Allergic Rhinitis Due to House Dust Mite
Allergic Rhinitis Due to Dermatophagoides Pteronyssinus
Other: Placebo
Biological: Sublingual allergy immunotherapy tablet

This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μ...

Enrolling
Bilateral Nasal Polyposis
Drug: OPN-375

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Inhaled Long-Acting Muscarinic Antagonist

Trial sponsors

Novartis logo

Novartis (4 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems